Daily Newsview all

Friday, July 29, 2016

ARISTOTLE Analysis: Don’t Shy Away From Standard Apixaban Dose in Certain High-Risk Patients

By Todd Neale

The standard dose is safe and effective in patients with just one of three criteria used to decide who should get a reduced dose, new analysis suggests.

 
Friday, July 29, 2016

Apollo Lunar Astronauts Dying of Heart Disease Pose CV Safety Questions for Deep Space

By Michael O'Riordan

While space travel does carry CV risks, this study is limited by its small sample size and included just three CV deaths, says one expert.

 
Thursday, July 28, 2016

TCTMD’s Top 10 Most Popular Stories for July 2016

By Shelley Wood
FDA news was popular among TCTMD readers this month, in particular our coverage of the agency’s approval of the Absorb bioresorbable scaffold.
Thursday, July 28, 2016

Thrombus Relatively Common After LAA Occlusion With Amplatzer Amulet, Small Study Suggests

By Todd Neale
The results are “quite surprising” and not consistent with what has been seen in other, larger series, one expert says.
Thursday, July 28, 2016

The Billions Spent on Healthcare for Sedentary Citizens Warrants Global Response

By L.A. McKeown
Exercise promotion and new cost-effective strategies are needed to reduce the pandemic of diabetes, heart problems, and other diseases related to inactivity.
Thursday, July 28, 2016

‘Reassuring’ 18-Month Results Seen With Absorb BVS, but Longer-Term Follow-up Still Needed

By Michael O'Riordan
In the EXPAND BVS registry, the MACE rate was comparable to that of second-generation DES, but the rate of scaffold thrombosis was still higher.
Wednesday, July 27, 2016

Blood Test May Be Useful for Detecting Aortic Regurgitation During TAVR

By L.A. McKeown
The screening method was used in real time to help operators quickly and efficiently correct valve issues—another boost for minimalist TAVR.
Wednesday, July 27, 2016

New PFO Guidelines: No Routine Offer of Closure for Cryptogenic Stroke, Says American Academy of Neurology

By Shelley Wood
The strong stance is at odds with an FDA advisory panel vote that tilted in favor of recommending approval of the Amplatzer PFO occluder.
Wednesday, July 27, 2016

Another Meta-Analysis Supports Prolonged Bivalirudin Use in STEMI, but Is Contemporary PCI Reflected?

By Yael L. Maxwell
Results from six trials combined show lower mortality and bleeding with continued bivalirudin, with no increased risk of acute stent thrombosis.
Wednesday, July 27, 2016

Public Reporting: Policy Changes in New York May Have Boosted PCI Rates of MI Complicated by Cardiogenic Shock

By Todd Neale
Despite the gains, rates continue to lag in New York compared with states that do not publicly report PCI mortality data.

Conference Newsview all

Monday, June 20, 2016 | Source: TVT 2016

Teenage TAVR: Should Practice Forge on While Guidelines Grow Up?

By Michael O'Riordan
Some key questions need to answered, not the least of which is the durability of the implanted valves.
Monday, June 20, 2016 | Source: TVT 2016

When Is Sick Too Sick for TAVR? Physicians Grapple With Identifying Futile Care

By Michael O'Riordan

Even among the most high-risk patients, some might be willing to undergo TAVR if it provides meaningful improvements in quality of life, say experts.

Monday, June 20, 2016 | Source: TVT 2016

Valve Degeneration Data Dearth Spurs Calls for Universal Definitions and Clinical Guidance

By Shelley Wood
A second look at TAVR valve degeneration from the sites that did the earliest cases is stirring the debate over which definitions should be used.
Saturday, June 18, 2016 | Source: TVT 2016

Not All Valves With Leaflet Thickening Develop Mobility Problems, Repeat 4D CT Shows in SAVORY

By Michael O'Riordan
As in other reports, oral anticoagulation with warfarin appears to protect patients from developing subclinical leaflet thickening after TAVR and surgery.
Friday, June 17, 2016 | Source: TVT 2016

To Intervene or Not to Intervene When the TAVR Patient Has CAD: New Insights

By Shelley Wood
Interventional cardiologists appear to have moved on from the see-it, fix-it approach of the past, but randomized clinical trial data are pending.
Friday, June 17, 2016 | Source: TVT 2016

What TAVR Needs Next . . . and What It’s Getting

By Shelley Wood

Amid talk of TAVR’s “relentless” march to low-risk patients at TVT 2016, experts unveiled the low-risk study designs and offered some notes of caution.

Thursday, June 16, 2016 | Source: TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

By Michael O'Riordan
In the single-center series, a simplified approach cut the average cost of TAVR by $10,000 without increasing the risk of death or stroke at 30 days.
Wednesday, June 08, 2016 | Source: EAS 2016

Non-HDL Cholesterol, Inflammation Appear to Be Linked in Patients Undergoing Elective PCI

By Yael L. Maxwell
A single-center study suggests that physicians should look beyond LDL when monitoring cholesterol.
Tuesday, June 07, 2016 | Source: EAS 2016

Nutrition and Physical Activity: The ‘Low-Hanging Fruit’ for Cardiologists Programmed to Prescribe Pills

By Yael L. Maxwell
Nonpharmaceutical strategies for modifying cardiometabolic risk should be discussed with patients, although a paucity of hard data plagues the field.
Monday, June 06, 2016 | Source: EAS 2016

Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts

By Yael L. Maxwell
The new ESC guidelines uphold specific lipid goals, emphasize lifestyle interventions, and advocate for population-based strategies.